Neutropenia. Neutrophil count decreases were also observed in randomized phase III trials of PARP inhibitors, especially with niraparib and talazoparib, but G ≥ 3 events were not frequent and febrile neutropenia was rare [25,26]. Here, PARP1 is linked to neutropenia.